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Abstract
Background: The cause and pathophysiology of ulcerative colitis are both mainly unknown. We
have previously used whole-genome microarray technique on biopsies obtained from patients with
ulcerative colitis to identifiy 5 changed mucosal transcripts. The aim of this study was to compare
mucosal expressions of these five transcripts in ulcerative colitis patients vs. controls, along with
the transcript expression in relation to the clinical ulcerative colitis status.
Methods:  Colonic mucosal specimens from rectum and caecum were taken at ambulatory
colonoscopy from ulcerative colitis patients (n = 49) with defined inflammatory activity and disease
extension, and from controls (n = 67) without inflammatory bowel disease. The five mucosal
transcripts aldolase B, elafin, MST-1, simNIPhom and SLC6A14 were analyzed using quantitative
real-time PCR.
Results:  Significant transcript differences in the rectal mucosa for all five transcripts were
demonstrated in ulcerative colitis patients compared to controls. The grade of transcript
expression was related to the clinical disease activity.
Conclusion: The five gene transcripts were changed in patients with ulcerative colitis, and were
related to the disease activity. The known biological function of some of the transcripts may
contribute to the inflammatory features and indicate a possible role of microbes in ulcerative colitis.
The findings may also contribute to our pathophysiological understanding of ulcerative colitis.
Background
Ulcerative colitis (UC) is a disorder characterized by
chronic mucosal inflammation of the large intestine. It is
frequently associated with various extraintestinal manifes-
tations. The inflammation may be limited to the rectum
(proctitis), but mucosal lesions often continue more prox-
imally (left-sided UC) or additionally embrace the trans-
verse colon (extensive colitis) or the entire large bowel
(pancolitis). The immune and cellular (non-immune)
response is dysregulated in both the acute and the chronic
phase of UC [1,2]. In Scandinavia, UC has been found to
affect individuals of all ages, with an annual incidence of
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about 15 per 100 000 [3,4] and a prevalence of about 300
per 100 000 inhabitants [5].
The pathogenesis and pathophysiology of UC are still
under investigation [6]. We can tentatively say that the
cause and onset of the disease is polygenic with environ-
mental interaction; that is, there is a genetic predisposi-
tion [7-9] in combination with eliciting environmental
factors which may precipitate the phenotype of UC [10].
In addition, interaction between the colonic epithelium
and microbiological flora as well as a disintegrated
mucosal barrier function may be important factors in the
onset and development of UC [6]. The use of microarray
technique analyses on mucosal specimens obtained from
both patients with established UC and controls has
allowed identification of candidate genes, which are valu-
able in research on UC pathogenesis. However, these UC
candidate genes must be carefully selected, since recent
evaluations of microarray data have revealed considerable
divergence after examination of similar tissues [11-13].
Such divergent results are commonly presented in studies
using pooled patient samples. In the present study how-
ever, the transcripts selected are based on our earlier indi-
vidual whole-genome microarray screening and
quantitative real-time PCR (RT-PCR) in patients with UC
[14], where five changed genes/transcripts were identified;
aldolase B, elafin, MST-1, simNIPhom (similar to NIP
homolog), and SLC6A14. The pathophysiological proper-
ties of SimNIPhom have not yet been clarified, but the
other transcript products have potential importance in
secretion [15,16], anti-microbiological activity [17], and
cell-mediated immune response [18].
The primary aim of the present study was to define differ-
ences in the mucosal expression of five selected tran-
scripts, retrieved from two different colonic locations in
UC, by using a quantitative RT-PCR technique. We also
aimed to evaluate the influence of ongoing anti-inflam-
matory treatment as well as the importance of the colonic
UC extension and the severity class.
Methods
Patients and tissue specimens
Before the colonoscopy procedure, consecutive male and
female subjects (UC patients and controls, >18 y) were
recruited to the present study. The UC diagnosis was
based on the medical history, endoscopic findings, histo-
logical examination, laboratory tests, and the clinical dis-
ease presentation. The extent of UC and the clinical
activity were classified in accordance with the Montreal
Classification [19]. In brief, the colonic inflammatory
involvement is defined as extension (letter E) combined
with a number between 1–3 (E1 denotes proctitis, E2 left-
sided UC, and E3 extensive colitis). In addition, the clini-
cal severity grade (letter S) is defined. The S-score ranges
from clinical remission (S0) to severe UC (S3). Mucosal
biopsies were obtained from the rectum (10–15 cm prox-
imal from anal verge) and caecum from all participants.
No uses of corticosteroids, aminosalicylates, or immuno-
suppressants were registered in the control group, while 9
patients (18%) in the UC group were treated systemically
with corticosteroids (prednisolone 10–20 mg). Twenty-
seven UC patients (55%) were treated systemically with
aminosalicylates (mesalazine 1.600–2.400 mg/24 h).
Among these, two patients had additional ongoing ther-
apy with aminosalicylate (mesalazine 500 mg QD) ene-
mas and three patients were treated with corticosteroid
enemas (prednisolone 37.5 mg QD or BID). Seven
patients had stable (>3 months) ongoing immunosup-
pressant treatment (Azathioprine, 1.8–2.2 mg/kg bw).
The remaining demographic and clinical data are pre-
sented in Figure 1.
RNA isolation
The biopsy specimens were immediately stored in RNA-
later solution for isolation of RNA. The RNA-later-pre-
served biopsies were homogenized in a lysis buffer from
the GenElute Mammalian Total RNA kit (Sigma, St. Louis,
MO.) and total RNA was isolated according to the manu-
facturer's instructions. The RNA concentration was meas-
ured spectrophotometrically.
Quantification by real-time polymerase chain reaction 
(RT-PCR)
Two μg of total RNA from each sample were converted
into cDNA. The cDNA synthesis was performed as
described previously [20]. Oligonucleotide primers pur-
chased from MWG-BIOTECH AG (Ebersberg, Germany)
were used for the relative quantification (ABI-7500 sys-
tem, software version 1.3) (Table 1). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as a refer-
ence gene in all experiments. The expression level in each
sample was compared with a calibrator by using the ΔΔCT-
formula (ΔCT(calibrator) - ΔCT(sample)).
Statistical analysis
Descriptive statistics and the Wilcoxon signed rank test
(SAS, Statview®) were used. Median values are presented.
Ethics
The study was approved by the local research ethical com-
mittee. All patients were given oral and written informa-
tion before entering the study. Informed consent was
obtained from all patients and controls.
Results
The mean duration of UC was 9.3 years (proctitis 9.6
years, left-sided colitis 9.5 years and extensive colitis/pan-BMC Gastroenterology 2008, 8:34 http://www.biomedcentral.com/1471-230X/8/34
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colitis 9.2 years). Neither age nor gender was matched
between the UC group and the control group.
In order to evaluate any differences in transcript expres-
sions within the control group (n = 67) with respect to
background diagnoses (anaemia, diverticulosis, irritable
bowel disease and polyposis), statistical analysis of each
background diagnosis were compared to the remaining
group of controls. No significant differences (p > 0.05)
were detected for any of these diagnoses.
Significantly higher transcript expressions of aldolase B
and SimNIPhom and significantly lower transcript expres-
sions of elafin, MST-1, and SLC6A14 were found in caecal
biopsies in comparison to rectal biopsies from the control
group (Figure 2). The only significant differences between
rectal and caecal transcript expressions in UC patients
were the decreased transcript expressions of elafin and
SLC6A14 in caecal biopsies in comparison to rectal biop-
sies.
Demographic and clinical data from the control and UC group respectively Figure 1
Demographic and clinical data from the control and UC group respectively.
Analyzed cases, n=116
Controls, n=67
Demographic data
Men: mean age; 68 (31-86), n=31
Women: mean age; 62 (19-88), n=36
Smoking habits
Current smokers;  n=9
Non-smokers; n=46
Ex-smoker; n=12
Reasons for colonoscopy
1Unexplained anemia; n=21
2Abdominal pain; n=24
3Suspect diverticulosis; n=21
4Post volvolus control; n=1
Colonoscopy diagnosis
1Normal endoscopic findings; n=5
Single adenomas; n=16
2IBS; n=24
3Diverticulosis; n=21
5Status post volvolus; n=1
Ulcerative colitis, n=49
Demographic data
Men: mean age; 49 (22-86), n=31
Women: mean age; 41 (21-71), n=18
Smoking habits
Current smokers;  n=4
Non-smokers; n=30
Ex-smoker; n=15
Montreal classification
(number of patients)
E1   E2    E3     Sum
S0 2      2     17        21
S1 2      3     5         10
S2 2      2     3          7
S3 1      2     8         11
Sum 7      9     33BMC Gastroenterology 2008, 8:34 http://www.biomedcentral.com/1471-230X/8/34
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Comparison of rectal biopsies from controls (n = 67) with
rectal biopsies from UC patients with inflammatory activ-
ity in accordance with Montreal classifications S1–S3 (n =
28) showed significant elevations (p < 0.05) in UC
patients of all transcript expressions with the exception of
MST-1, which showed significantly (p < 0.05) decreased
expression in UC patients. The same analysis of caecal
biopsies from controls and patients with S1–S3 UC (n =
16) showed significantly elevated transcript expressions of
aldolase B and SLC6A14 only. Distal biopsies from con-
trols, compared with UC patients without inflammatory
activity (S0), showed increased transcript expression in
aldolase B only (median -1.62 vs. 1.0, p = 0,012). All other
transcript analyses from both locations showed no signif-
icant differences (p > 0.05).
All transcript analysis with respect to UC extension
showed that left-sided (E2) and total colitis (E3) differed
significantly from controls (p < 0.05); this was not the
case for proctitis (E1).
Table 1: Primers used for real-time polymerase chain reaction.
Gene Forward primer Reverse primer
Aldolase B 5'-aaggctgcaaacaaggaggcaacc-3' 5'-tgaagagcgactgggtggaagcag-3'
Elafin 5'-tgtgaaggctcttgcgggatgg-3' 5'-agggcagcagggacttaggaccag-3'
SimNIPhom 5'-cgccagacagctaggggagtgaag-3' 5'-gcatttctgatattttgtgaccacgcac-3'
SLC6A14 5'-gctgcttggttttgtttctccttggtc-3' 5'-gcaattaaaatgccccatccagcac-3'
MST-1 5'-aaccaggagtgtaacatcaagcaccgag-3' 5'-cagttgtgggtaaagcaggcaagtgg-3'
GAPDH 5'-gagcaccaggtggtctcctctgacttc-3' 5'-gccaaattcgttgtcataccaggaaatg-3'
RT-PCR result (ΔΔCt(=ΔCttarget-ΔCtcalibrator)) for controls (filled dots) and UC patients (▲) presented as median values and  25th and 75th percentil (bars) Figure 2
RT-PCR result (ΔΔCt(=ΔCttarget-ΔCtcalibrator)) for controls (filled dots) and UC patients (▲) presented as 
median values and 25th and 75th percentil (bars). * = p < 0.05, ** = p < 0.01, *** = p < 0.001, n.s. = non significant. Ref-
erence gene: GAPDH.BMC Gastroenterology 2008, 8:34 http://www.biomedcentral.com/1471-230X/8/34
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Statistical analysis concerning the influence of anti-
inflammatory treatment on the transcript expressions
within the UC cohort showed no statistical differences (p
> 0.05) when comparing UC patients with ongoing corti-
costeroids (n = 9) or azathioprine (n = 7) respectively with
the remaining UC patients. However, the 27 patients
treated with mesalazine show a significant increase in
aldolase B (median 0.48 vs. 3.02, p = 0.035) in compari-
son to the remaining UC patients.
Discussion
Genetic predisposition, psychological stress, nutritional
and environmental influences, intestinal pathogens and
disturbed intestinal barrier function have all been propo-
seas pathogenetic factors in UC [6]. However, current
knowledge about the pathogenesis and pathophysiology
of UC [21] is incomplete. Moreover, with the exception of
a few general serological inflammatory activity biomark-
ers, even less information is available regarding mucosa-
associated transcript changes and their potential pathoge-
netic and pathophysiological role in UC [22]. This lack of
knowledge may sometimes lead to uncertainty in diagno-
sis, judgement of prognosis and clinical management of
UC patients.
On the basis of exsisting knowledge of the biological func-
tions of the transcripts investigated in this study, it is rea-
sonable to believe that the demonstrated alterations
might be related to predisposition and/or the pathophys-
iological response in UC.
It is intriguing that aldolase B and SLC6A14 were up-reg-
ulated in rectal as well as caecal mucosa in UC compared
to controls. Aldolase B is known to be mainly expressed in
the intestinal villus cells and it has a central role in the gly-
colytic pathway. It also participates in regulation of intes-
tinal secretion [16]. Since SLC6A14 is also known to
encode a Na+/Cl- driven amino acid transporter B(0+)
[15], the up-regulation of aldolase B and SLC6A14 might
be a common pathophysiological response, aimed at
counteracting the exaggerated loss of fluid seen in UC.
Theoretically, the up-regulation of these two transcripts
could be a local response to the increased feacal/fluid
stream, where bioactive molecules comprise ability to reg-
ulate transcript expression. Additionally, since the inflam-
matory activity and load of fluid over time is usually most
pronounced in the distal part of the colon, the registered
changes in aldolase B and SLC6A14 may reflect long-term
inflammatory activity. Our finding that aldolase B from
distal biopsies is significantly elevated during the remis-
sion phase (S0) indicates that the regulation of this tran-
script not only is secondary to the inflammatory activity.
The involvement of the microflora and its importance in
the onset, development and preservation of UC has been
discussed [6]. The SLC6A14 transcript expression is there-
fore also interesting in this respect, since it is involved in
the host's antibacterial response [21]. In addition, the
defensine-like epithelium associated antimicrobial mole-
cule elafin, antagonizing human neutrophil elastase pre-
venting tissue injury via inhibition of excessive release of
proteolytic enzymes from inflammatory cells is interest-
ing in this context [18]. The present results confirm an
elafin transcript enhancement in caecal as well as rectal
biopsies from patients with UC. Thus, the combined ele-
vation of elafin and SLC6A14 may contribute to an ampli-
fied defence reaction aimed to restoration and
maintenance of the mucosal integrity. This finding may
indicate a pathogenetic role of the microflora in UC.
MST-1 was included in the present study due to its altera-
tions in UC, as shown in our previous experiment [14],
although it was excluded from that publication due to
deviation in its control group. MST-1 is known to be capa-
ble of inhibiting cell-mediated immune responses via
down-regulation of IL-12 production and subsequently
inhibition of macrophage activation [23]. Consequently,
the observed down-regulation of MST-1 in rectal speci-
mens may contribute to an enhanced cellular immune
response in UC. A reasonable explanation of the concom-
itant decreased MST-1 transcript expression and increased
aldolase B, SLC6A14, and elafin transcript expression is
that the changes describe a pathophysiological response
to a more pronounced inflammatory and, possibly, an
exaggerated microbial load in at least the rectal part of the
colon mucosa.
The fifth identified significantly up-regulated transcript
(in rectum only) SimNIPhom (similar to the numb-inter-
acting homolog), encodes a hypothetical protein, at
present of unknown pathophysiological importance.
Our results supports that specimens from the rectal
mucosa are more suitable for further analysis of the
selected transcripts, due to the more predictable inflam-
matory involvement in the rectum and its availability for
direct inspection and easy biopsy sampling.
Our data can not answer whether the observed changes in
expressions of the five selected transcripts may be present
in e.g. other inflammatory, infectious or autoimmune
conditions since this study uniquely focused on UC
patients compared to non-inflamed controls.
Conclusion
The five changed gene transcript expressions have relation
to UC, its extension and clinical severity. Whether the pre-
sented results will contain discriminative potential of
importance for the medical care of patients with UC in
future clinical practice remains to be elucidated.Publish with BioMed Central    and   every 
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